Cost‐effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon

摘要: Summary Background : The efficacy of combination therapy in patients with chronic hepatitis C previously not responding to interferon monotherapy is lower than that naive patients, and there has been no economic evaluation this population. Aim : To develop a cost-effectiveness analysis therapeutic regimens interferon-alpha ribavirin previous non-responders. Methods : A Markov simulation model was used project the clinical outcomes five different strategies, including ‘no treatment’ alternative, using health care system perspective. The data for doses durations were obtained from performed meta-analysis. A sensitivity test robustness model, analysing changes variables. Results : Applying 3% discount rate, standard patient on 12 months showed increases 0.80 years 1.55 quality-adjusted life years, when compared strategy. This option led an incremental ratio 11 767 euros per year gained 6073 year. Conclusions : Combination plus cost-effective non-responders within range some well-accepted medical interventions our system.